Mitomycins
-
Subject Areas on Research
- A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
- Activation of human B lymphocytes. V. Kinetics and mechanisms of suppression of plaque-forming cell responses by concanavalin A-generated suppressor cells.
- Alterations in endothelial superoxide dismutase levels as a function of growth state in vitro.
- Blocking of autologous and homologous leukocyte responses by human alloimmune plasmas: a possible in vitro correlate of enhancement.
- Characterization of human chemotactic lymphokine production induced by mitogens and mixed leukocyte reactions using a new microassay.
- Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice.
- DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1.
- Effects of donor splenocytes treated with mitomycin C on rat hepatic, cardiac, and intestinal allografts.
- Gastroduodenal ulcerations in patients receiving selective hepatic artery infusion chemotherapy.
- Human IgE synthesis in vitro: a reassessment.
- Intracavitary mitomycin-C in the treatment of superficial urothelial tumors: a preliminary report.
- Intragenic regulation of the synthesis of phi chi 174 gene A proteins.
- Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma.
- Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
- Management of locally advanced adenocarcinoma of the pancreas.
- Measurement of the DNA synthetic capacity of activated lymphocytes: nucleotide triphosphate incorporation by permeabilized cells.
- Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results.
- Migrating keratinocytes express urokinase-type plasminogen activator.
- Mitomycin-induced hemolytic-uremic syndrome.
- Non-specific and specific active immunotherapy in a B16 murine melanoma system.
- Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
- Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer.
- Treatment of superficial carcinoma of the bladder.
- Variable allograft responses to pretreatment with donor splenocytes treated with mitomycin C in the rat.